On Wednesday, Piper Sandler adjusted its outlook on shares of Karyopharm Therapeutics (NASDAQ:KPTI), increasing the price target to $5.00 from the previous $4.00 while maintaining an Overweight rating on the stock. This revision follows Karyopharm's announcement of its third-quarter financial results, which showed a significant total revenue beat and Xpovio net product revenues aligning with expectations.
The company's management has refined their forecasts for both total revenue and U.S. Xpovio net product revenue, tailoring them to current operating plans and commercial performance thus far. Despite facing competitive pressures, Karyopharm has been successful in the commercial execution of Xpovio, its cancer treatment drug.
Clinical timelines for Karyopharm's pipeline remain consistent with prior projections by the management. However, the expected timing for top-line results from the Phase 3 multiple myeloma study is uncertain. This uncertainty stems from an amended trial protocol that has been submitted to the U.S. Food and Drug Administration (FDA) for approval.
Piper Sandler's analyst expressed a positive stance on Karyopharm's commercial and clinical progress. The firm's recommendation to keep shares overweight is backed by the company's favorable clinical setup and the recent performance of Xpovio. The new stock price target of $5.00 reflects an adjustment due to the partial lapse in the discounting period associated with the company's stock valuation.
In other recent news, Karyopharm Therapeutics Inc. has announced changes to its Phase 3 SENTRY trial for myelofibrosis, now measuring the absolute total symptom score (Abs-TSS) over a 24-week period as one of its co-primary endpoints.
This shift follows guidance from the U.S. Food and Drug Administration (FDA) and is supported by key investigators and patient advocacy organizations. The trial will continue to evaluate the efficacy of selinexor in combination with ruxolitinib, with top-line data expected in the second half of 2025.
In addition to the trial modification, Karyopharm is facing the risk of delisting from the Nasdaq Global Select Market due to its stock price not meeting the minimum bid price. However, the pharmaceutical company has until March 17, 2025, to regain compliance. The company is also undergoing a leadership transition with the resignation of Michael Mason, the Executive Vice President, Chief Financial Officer, and Treasurer, effective November 5, 2024.
Two distinct firms, H.C. Wainwright and RBC Capital, have revised Karyopharm's financial outlook. H.C. Wainwright has adjusted the company's price target to $7.00 from $8.00, maintaining a Buy rating and slightly improving the full-year 2024 earnings per share (EPS) estimate.
RBC Capital has maintained an Outperform stock rating, highlighting the potential of the drug selinexor and projecting U.S. sales potential of $400-500 million. These recent developments indicate a period of significant change for Karyopharm Therapeutics.
InvestingPro Insights
While Piper Sandler maintains an optimistic outlook on Karyopharm Therapeutics, InvestingPro data and tips offer additional context for investors. Despite the company's revenue growth of 1.77% over the last twelve months, Karyopharm faces significant financial challenges. The company's market capitalization stands at $105.44 million, reflecting its current valuation in the market.
InvestingPro Tips highlight that Karyopharm is quickly burning through cash and is not expected to be profitable this year. This aligns with the company's operating income margin of -89.89%, indicating substantial operational losses. Additionally, the company does not pay a dividend to shareholders, which may be a consideration for income-focused investors.
On a positive note, Karyopharm's liquid assets exceed its short-term obligations, providing some financial flexibility. This could be crucial as the company continues to invest in its pipeline and commercial execution of Xpovio.
For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips that could provide further insights into Karyopharm's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.